The trajectory of Sildenafil presents a intricate picture for investors. While the initial release generated substantial profits, the end of its patent opened the door to generic alternatives, dramatically diminishing https://1001bookmarks.com/story21494459/sildenafil-and-the-pharmaceutical-industry-a-risky-opportunity